CO2022010343A2 - Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico - Google Patents
Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónicoInfo
- Publication number
- CO2022010343A2 CO2022010343A2 CONC2022/0010343A CO2022010343A CO2022010343A2 CO 2022010343 A2 CO2022010343 A2 CO 2022010343A2 CO 2022010343 A CO2022010343 A CO 2022010343A CO 2022010343 A2 CO2022010343 A2 CO 2022010343A2
- Authority
- CO
- Colombia
- Prior art keywords
- chronic
- prophylactic
- therapeutic agent
- pain syndrome
- pelvic pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico, donde el agente contiene un inhibidor de mPGES-1 como ingrediente activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019233865 | 2019-12-25 | ||
PCT/JP2020/048479 WO2021132472A1 (ja) | 2019-12-25 | 2020-12-24 | 慢性前立腺炎/慢性骨盤痛症候群の予防及び/又は治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022010343A2 true CO2022010343A2 (es) | 2022-10-31 |
Family
ID=76575232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0010343A CO2022010343A2 (es) | 2019-12-25 | 2022-07-22 | Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230094705A1 (es) |
EP (1) | EP4082573A4 (es) |
JP (1) | JPWO2021132472A1 (es) |
KR (1) | KR20220120646A (es) |
CN (1) | CN114867495A (es) |
AU (1) | AU2020413313A1 (es) |
BR (1) | BR112022012485A2 (es) |
CA (1) | CA3165891A1 (es) |
CO (1) | CO2022010343A2 (es) |
EC (1) | ECSP22058286A (es) |
IL (1) | IL294191A (es) |
MX (1) | MX2022007936A (es) |
PE (1) | PE20230164A1 (es) |
WO (1) | WO2021132472A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
JP5579862B2 (ja) * | 2009-10-23 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミクロソームプロスタグランジンe2シンターゼ−1のインヒビター |
TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
BR112014003496B1 (pt) | 2011-08-18 | 2022-02-22 | Nippon Shinyaku Co., Ltd | Derivado heterocíclico, usos do mesmo e composição farmacêutica |
WO2013067296A1 (en) * | 2011-11-04 | 2013-05-10 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED | Method of treatment |
SG10201913525QA (en) * | 2015-10-29 | 2020-02-27 | Aska Pharmaceutical Co Ltd | Pyrimidine derivative |
-
2020
- 2020-12-24 MX MX2022007936A patent/MX2022007936A/es unknown
- 2020-12-24 BR BR112022012485A patent/BR112022012485A2/pt unknown
- 2020-12-24 AU AU2020413313A patent/AU2020413313A1/en active Pending
- 2020-12-24 US US17/788,516 patent/US20230094705A1/en active Pending
- 2020-12-24 CA CA3165891A patent/CA3165891A1/en active Pending
- 2020-12-24 JP JP2021567619A patent/JPWO2021132472A1/ja active Pending
- 2020-12-24 EP EP20905872.6A patent/EP4082573A4/en active Pending
- 2020-12-24 WO PCT/JP2020/048479 patent/WO2021132472A1/ja active Application Filing
- 2020-12-24 PE PE2022001326A patent/PE20230164A1/es unknown
- 2020-12-24 CN CN202080090316.8A patent/CN114867495A/zh active Pending
- 2020-12-24 KR KR1020227025732A patent/KR20220120646A/ko unknown
- 2020-12-24 IL IL294191A patent/IL294191A/en unknown
-
2022
- 2022-07-22 CO CONC2022/0010343A patent/CO2022010343A2/es unknown
- 2022-07-25 EC ECSENADI202258286A patent/ECSP22058286A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220120646A (ko) | 2022-08-30 |
WO2021132472A1 (ja) | 2021-07-01 |
AU2020413313A1 (en) | 2022-07-14 |
EP4082573A4 (en) | 2024-01-10 |
ECSP22058286A (es) | 2022-09-30 |
US20230094705A1 (en) | 2023-03-30 |
CA3165891A1 (en) | 2021-07-01 |
IL294191A (en) | 2022-08-01 |
PE20230164A1 (es) | 2023-02-01 |
JPWO2021132472A1 (es) | 2021-07-01 |
BR112022012485A2 (pt) | 2022-09-06 |
MX2022007936A (es) | 2022-10-27 |
EP4082573A1 (en) | 2022-11-02 |
CN114867495A (zh) | 2022-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008197A (es) | Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. | |
BR112018016729A2 (pt) | novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase | |
PH12019502646A1 (en) | Pyrazole magl inhibitors | |
CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
CL2021000047S1 (es) | Masajeador. | |
MY193312A (en) | Topical formulation for promoting wound healing | |
CO2021003103A2 (es) | Composiciones oleaginosas tópicas | |
CL2009000660A1 (es) | Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor. | |
CL2021000529A1 (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
AR109407A1 (es) | Compuesto de 1-acetil-3-fenilurea y su uso | |
CO2020001881A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol | |
CY1122979T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης | |
MX2018005350A (es) | Formulacion de combinacion de dosis fija, eflornitina y sulindaco. | |
ECSP22058286A (es) | Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico | |
PH12019502145A1 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient | |
AR109406A1 (es) | Compuesto de 1-fenil-3-carbamoilurea y su uso | |
PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
SV2016005308A (es) | Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
SG11201907124YA (en) | Anti-inflammatory agent | |
AR109409A1 (es) | Compuesto de 3-piridiloxifenildihidrouracilo y su uso | |
AR109405A1 (es) | Compuestos de fenilurea y su uso |